NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Jul 25 2022

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

This approval is for a generic version of Jevtana Kit, specifically for a certain strength of the product. The company has not disclosed the launch date for the product due to confidentiality. The press release also mentions that Jevtana Kit generated significant annual sales in the previous year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases